The German company that launched thalidomide is poised for a breakthrough deal that could help sharply reduce the abuse of prescription drugs by unauthorised users.

Sebastian Wirtz, head of Grunenthal, said his company could by the end of this year sign a deal to combine its ”tamper-resistant formulation” technology with a medicine produced by another pharmaceutical company. He declined to name the company ahead of any announcement.